|
1.
|
|
1 p, 257.6 KB |
Publisher Correction : Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study
/
Kayser, Sabine (Heidelberg University Hospital (Alemanya)) ;
Rahmé, Ramy (Université Paris Diderot. Hôpital Saint Louis) ;
Martínez-Cuadrón, David (Centro de Investigación Biomédica en Red de Cáncer) ;
Ghiaur, Gabriel (Johns Hopkins University) ;
Thomas, Xavier (Centre Hospitalier Lyon-Sud) ;
Guerci-Bresler, Agnes (Nancy University Hospital) ;
Garrido, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Pigneux, Arnaud (Bordeaux University Hospital) ;
Gil, Cristina (Hospital General, Alicante) ;
Raffoux, Emmanuel (Université Paris Diderot) ;
Tormo, Mar (Universitat de València) ;
Vey, Norbert (Institut Paoli Calmette) ;
de la Serna, Javier (Hospital 12 de Octubre (Madrid)) ;
Salamero, Olga (Hospital Universitari Vall d'Hebron) ;
Lengfelder, Eva (University Hospital Mannheim) ;
Levis, Mark (Johns Hopkins University) ;
Fenaux, Pierre (Université Paris Diderot) ;
Sanz, Miguel A. (Centro de Investigación Biomédica en Red de Cáncer) ;
Platzbecker, Uwe (University Hospital Leipzig. Medical Clinic and Policlinic I, Hematology and Cellular Therapy) ;
Schlenk, Richard F. (NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center and Heidelberg University Hospital) ;
Adès, Lionel (Université Paris Diderot) ;
Montesinos, Pau (Centro de Investigación Biomédica en Red de Cáncer) ;
Universitat Autònoma de Barcelona
2021 -  10.1038/s41375-021-01358-3
Leukemia, Vol. 35 (november 2021) , p. 3631
|
|
|
2.
|
|
1.2 MB |
Molecular landscape and prognostic impact of FLT3 -ITD insertion site in acute myeloid leukemia : RATIFY study results
/
Rücker, Frank G. (Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany) ;
Du, Ling (Novartis Pharmaceuticals, Cambridge) ;
Luck, Tamara J. (Charité University, Berlin) ;
Benner, Axel (German Cancer Research Center, Heidelberg) ;
Krzykalla, Julia (German Cancer Research Center, Heidelberg) ;
Gathmann, Insa (Novartis Pharmaceuticals, Basel) ;
Voso, Maria Teresa (Università di Roma "Tor Vergata", Rome) ;
Amadori, Sergio (Università di Roma "Tor Vergata", Rome) ;
Prior, Thomas W. (The Ohio State University Comprehensive Cancer Center, Columbus) ;
Brandwein, Joseph M. (University of Alberta, Edmonton) ;
Appelbaum, Frederick R. (Fred Hutchinson Cancer Research Center, Seattle) ;
Medeiros, Bruno (Stanford University) ;
Tallman, Martin S. (Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York) ;
Savoie, Lynn (University of Calgary, Calgary) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Pallaud, Celine (Novartis Pharmaceuticals, Basel) ;
Sanz, Miguel A. (Hospital Universitari i Politècnic La Fe, València) ;
Jansen, Joop H. (Radboud University Medical Center, Nijmegen) ;
Niederwieser, Dietger (Hematology and Oncology, University of Leipzig, Leipzig) ;
Fischer, Thomas (Otto-von-Guericke University Magdeburg, Magdeburg) ;
Ehninger, Gerhard (Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden) ;
Heuser, Michael (Hannover Medical School, Hannover) ;
Ganser, Arnold (Oncology and Stem Cell Transplantation, Hannover) ;
Bullinger, Lars (Charité University, Berlin) ;
Larson, Richard A. (University of Chicago, Chicago) ;
Bloomfield, Clara D. (The Ohio State University Comprehensive Cancer Center, Columbus) ;
Stone, Richard M. (Dana-Farber/Partners CancerCare, Boston) ;
Döhner, Hartmut (University Hospital of Ulm) ;
Thiede, Christian (Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden) ;
Döhner, Konstanze (University Hospital of Ulm) ;
Universitat Autònoma de Barcelona
In acute myeloid leukemia (AML) internal tandem duplications of the FLT3 gene (FLT3- ITD) are associated with poor prognosis. Retrospectively, we investigated the prognostic and predictive impact of FLT3 -ITD insertion site (IS) in 452 patients randomized within the RATIFY trial, which evaluated midostaurin additionally to intensive chemotherapy. [...]
2021 - 10.1038/s41375-021-01323-0
Leukemia, Vol. 36 (july 2021) , p. 90-99
|
|
|
3.
|
|
9 p, 621.5 KB |
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study
/
Kayser, Sabine (Heidelberg University Hospital. Department of Internal Medicine V) ;
Rahmé, Ramy (Université Paris Diderot) ;
Martínez-Cuadrón, David (Centro de Investigación Biomédica en Red de Cáncer) ;
Ghiaur, Gabriel (Johns Hopkins University) ;
Thomas, Xavier (Centre Hospitalier Lyon-Sud. Hospices Civils de Lyon) ;
Sobas, Marta (Wroclaw Medical University) ;
Guerci-Bresler, Agnes (Nancy University Hospital) ;
Garrido, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Pigneux, Arnaud (Bordeaux University Hospital) ;
Gil, Cristina (Hospital General, Alicante, Spain) ;
Raffoux, Emmanuel (Université Paris Diderot. Hôpital Saint Louis) ;
Tormo, Mar (Hospital Clínic Universitari (València)) ;
Vey, Norbert (Institut Paoli Calmette) ;
de la Serna, Javier (Hospital 12 de Octubre (Madrid)) ;
Salamero, Olga (Hospital Universitari Vall d'Hebron) ;
Lengfelder, Eva (University Hospital Mannheim. Department of Hematology and Oncology) ;
Levis, Mark (Johns Hopkins University) ;
Fenaux, Pierre (Université Paris Diderot. Hôpital Saint Louis) ;
Sanz, Miguel A. (Centro de Investigación Biomédica en Red de Cáncer) ;
Platzbecker, Uwe (University Hospital Leipzig) ;
Schlenk, Richard F. (German Cancer Research Center and Heidelberg University Hospital) ;
Adès, Lionel (Université Paris Diderot) ;
Montesinos, Pau (Centro de Investigación Biomédica en Red de Cáncer) ;
Universitat Autònoma de Barcelona
Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73. [...]
2020 - 10.1038/s41375-020-0758-4
Leukemia, Vol. 34 (february 2020) , p. 2333-2341
|
|
|
4.
|
|
10 p, 1.8 MB |
Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma : Updated Overall Survival, Safety, and Subgroups
/
Orlowski, R.Z. (Department of Lymphoma and Myeloma. The University of Texas M.D. Anderson Cancer Center) ;
Moreau, P. (Department of Hematology. University Hospital Hotel-Dieu) ;
Niesvizky, R. (Department of Medical Oncology. Myeloma Center. New York Presbyterian Hospital-Weill Cornell Medical Center) ;
Ludwig, H. (Wilhelminen Cancer Research Institute (Viena, Àustria)) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Chng, W.J. (Department of Hematology Oncology. National University of Singapore) ;
Goldschmidt, H. (Department of Hematology Oncology. Heidelberg University Clinic and the National Center of Tumor Diseases) ;
Yang, Z. (Department of Biostatistics. Amgen. Inc) ;
Kimball, A.S. (Department of Clinical Research. Amgen. Inc) ;
Dimopoulos, M. (Department of Clinical Therapeutics. University Athens School of Medicine) ;
Universitat Autònoma de Barcelona
Introduction: The phase III RandomizEd, OpeN Label, Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib Plus DexamethasOne in Patients With Relapsed Multiple Myeloma (ENDEAVOR) trial showed significantly improved progression-free survival and overall survival (OS) with carfilzomib (56 mg/m) and dexamethasone (Kd56) versus bortezomib and Kd56 (Vd) in patients with relapsed or refractory multiple myeloma (RRMM). [...]
2019 - 10.1016/j.clml.2019.04.018
Clinical Lymphoma, Myeloma & Leukemia, Vol. 19 Núm. 8 (august 2019) , p. 522-530.e1
|
|
|
5.
|
|
36 p, 6.5 MB |
CD133-directed CAR T-cells for MLL leukemia : on-target, off-tumor myeloablative toxicity
/
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zanetti, SR (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Baroni, Matteo Libero. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sánchez-Martínez, D. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Molina, Oscar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Closa, A. (Universitat Pompeu Fabra) ;
Agraz-Doblás, Antonio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Marín, P. (Hospital Clínic i Provincial de Barcelona) ;
Eyras, E. (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ;
Varela, I. (Instituto de Biomedicina y Biotecnología de Cantabria (CSIC-UC-Sodercan). Departamento de Biología Molecular. Universidad de Cantabria) ;
Menéndez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
2019 - 10.1038/s41375-019-0418-8
Leukemia, Vol. 33 Núm. 8 (january 2019) , p. 2090-2125
|
|
|
6.
|
|
13 p, 3.4 MB |
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
/
López-Millán, Belén (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sanchéz-Martínez, Diego (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Roca Ho, Heleia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Molina, Oscar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Díaz de la Guardia, Rafael (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Torres, Raul (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fuster, J.L. (Hospital Clínico Universitario Virgen de la Arrixaca (El Palmar, Múrcia)) ;
Ballerini, P. (Pediatric Hematology. Armand Trousseau Hospital) ;
Suessbier, U. (Hematology Department. University Hospital-University of Zurich) ;
Nombela-Arrieta, C. (Hematology Department. University Hospital-University of Zurich) ;
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Menéndez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
B cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, with cure rates of ∼80%. MLL-rearranged (MLLr) B-ALL (MLLr-B-ALL) has, however, an unfavorable prognosis with common therapy refractoriness and early relapse, and therefore new therapeutic targets are needed for relapsed/refractory MLLr-B-ALL. [...]
2019 - 10.1038/s41375-018-0353-0
Leukemia, Vol. 33 Núm. 7 (january 2019) , p. 1557-1569
|
|
|
7.
|
|
12 p, 1.8 MB |
Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option : a cross-study comparison of the CANDOR and EQUULEUS studies
/
Leleu, X. (Service d'Hématologie et Thérapie cellulaire. CHU and Inserm) ;
Beksac, M. (Department of Hematology. Ankara University) ;
Chou, T. (Niigata Cancer Center Hospital) ;
Dimopoulos, M. (Hematology and Medical Oncology. Department of Clinical Therapeutics. National and Kapodistrian University of Athens School of Medicine) ;
Yoon, S.S. (Department of Internal Medicine. Seoul National University) ;
Prince, H.M. (Epworth Healthcare and Sir Peter MacCallum Department of Oncology. University of Melbourne) ;
Pour, L. (Department of Internal Medicine. Hematology and Oncology. University Hospital Brno) ;
Shelekhova, T. (Clinic of Professional Pathology) ;
Chari, A. (Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica). Tisch Cancer Institute) ;
Khurana, M. (Clinical Development. Oncology. Amgen Inc) ;
Zhang, J. (Global Biostatistical Science. Amgen Inc) ;
Obreja, M. (Global Biostatistical Science. Amgen Inc) ;
Qi, M. (Hematology and Oncology. Janssen Research and Development. LLC) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Siegel, D. (John Theurer Cancer Center. Hackensack University Medical Center) ;
Universitat Autònoma de Barcelona
The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158688), whereas KdD at the once-weekly 70 mg/m carfilzomib dose (KdD70) was used in the phase 1 b EQUULEUS study (NCT01998971). [...]
2020 - 10.1080/10428194.2020.1832672
Leukemia and Lymphoma, 2020
|
|
|
8.
|
|
15 p, 3.4 MB |
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS
/
Kuendgen, A. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ;
Nomdedeu, Meritxell (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Tuechler, H. (Boltzmann Institute for Leukemia Research. Hanusch Hospital) ;
Garcia-Manero, G. (Department of Leukemia. MD Anderson Cancer Center) ;
Komrokji, R.S. (Department of Malignant Hematology. H Lee Moffitt Cancer Center) ;
Sekeres, M.A. (Leukemia Program. Department of Hematology and Medical Oncology. Taussig Cancer Institute. Cleveland Clinic) ;
Della Porta, M.G. (Cancer Center - IRCCS Humanitas Research Hospital & Humanitas University) ;
Cazzola, M. (Department of Hematology Oncology. IRCCS Policlinico San Matteo Foundation) ;
DeZern, A.E. (Sidney Kimmel Comprehensive Cancer Center. Johns Hopkins University) ;
Roboz, G.J. (Weill Cornell Medicine and The New York Presbyterian Hospital) ;
Steensma, D.P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Van de Loosdrecht, A.A. (Vrije Universiteit Amsterdam) ;
Schlenk, R.F. (Department of Internal Medicine V. Heidelberg University Hospital) ;
Grau, J. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Calvo, Xavier (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Blum, S. (Service of Hematology. University Hospital Lausanne) ;
Pereira, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Valent, P. (Department of Internal Medicine I. Division of Hematology & Hemostaseology and Ludwig Boltzmann Institute for Hematology and Oncology. Medical University of Vienna) ;
Costa, D. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Giagounidis, A. (Department of Oncology. Hematology and Palliative Care. Marienhospital Duesseldorf) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Döhner, H. (Department of Internal Medicine III. University Hospital Ulm) ;
Platzbecker, U. (University Hospital Leipzig) ;
Pedro, Carme (Hospital del Mar (Barcelona, Catalunya)) ;
Lübbert, M. (Department of Hematology. Oncology and Stem Cell Transplantation. University Medical Center Freiburg. Faculty of Medicine) ;
Oiartzabal, I. (Clinical Hematology Department. Hospital Universitario Araba) ;
Díez-Campelo, M. (Clinical Hematology Department. Hospital Universitario de Salamanca (HUSA)) ;
Cedena, M.T. (Hospital Universitario 12 de Octubre (Madrid)) ;
Machherndl-Spandl, S. (1st. Internal Department - Hematology with stem cell transplants. Hemostaseology and Medical Oncology. Elisabethinen Hospital) ;
López-Pavía, M. (Clinical Hematology Department. Hospital General Universitari de València) ;
Baldus, C.D. (Department of Hematology and Oncology. University Hospital Schleswig-Holstein. Campus Kiel) ;
Martinez-de-Sola, M. (Parc Taulí Hospital Universitari) ;
Stauder, R. (Department of Internal Medicine V (Hematology and Oncology). Innsbruck Medical University) ;
Merchan, B. (Hospital Universitari Vall d'Hebron) ;
List, A. (Department of Malignant Hematology. H Lee Moffitt Cancer Center) ;
Ganster, C. (Department of Hematology and Medical Oncology. University Medical Center Göttingen) ;
Schroeder, T. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ;
Voso, Maria Teresa (Department of Biomedicine and Prevention. Tor Vergata University) ;
Pfeilstöcker, M. (Hanusch Krankenhaus Wien) ;
Sill, H. (Medizinische Universität Graz) ;
Hildebrandt, B. (Institute of Human Genetics. University Duesseldorf) ;
Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Nomdedeu, B. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Cobo, F. (Clinical Hematology Department. Hospital Quirón Teknon) ;
Haas, R. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ;
Sole, F. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Germing, U. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ;
Greenberg, P.L. (Stanford University Cancer Center) ;
Haase, D. (Department of Hematology and Medical Oncology. University Medical Center Göttingen) ;
Sanz, G. (Hospital Universitari i Politècnic La Fe de Valencia) ;
Universitat Autònoma de Barcelona
In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic/myeloproliferative neoplasms into one subgroup independent of morphologic or prognostic features. [...]
2020 - 10.1038/s41375-020-0917-7
Leukemia, 2020
|
|
|
9.
|
|
5 p, 786.3 KB |
B-cell leukemia transdifferentiation to macrophage involves reconfiguration of DNA methylation for long-range regulation
/
Bueno-Costa, Alberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Piñeyro, David (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Soler, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Javierre, BM (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Raurell Vila, Helena (Institut Germans Trias i Pujol) ;
Subirana-Granés, Marc (Institut Germans Trias i Pujol) ;
Pasquali, Lorenzo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martinez-Climent, J.A. (Centro de Investigación Biomédica en Red de Cáncer) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
2020 - 10.1038/s41375-019-0643-1
Leukemia, Vol. 34 Núm. 4 (april 2020) , p. 1158-1162
|
|
|
10.
|
|
11 p, 1.4 MB |
Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma : an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials
/
Weisel, K. (Department of Hematology. Oncology. Immunology. Rheumatology. and Pulmonology. Medical Clinic II) ;
Majer, I. (Amgen Europe GmbH) ;
DeCosta, L. (Amgen Ltd) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Goldschmidt, H. (Internal Medicine V and National Center of Tumor Diseases. University Clinic Heidelberg) ;
Ludwig, H. (Wilhelminen Cancer Research Institute. Wilhelminenspital) ;
Campioni, M. (Amgen Europe GmbH) ;
Szabo, Z. (Amgen Europe GmbH) ;
Dimopoulos, M. (School of Medicine. National and Kapodistrian University of Athens. Alexandra Hospital) ;
Universitat Autònoma de Barcelona
In ENDEAVOR, carfilzomib and dexamethasone (Kd56) demonstrated significant improvement in progression-free survival (PFS) compared with bortezomib and dexamethasone (Vd). Both agents were administered until disease progression; the EU label for Vd, however, stipulates a maximum of eight treatment cycles. [...]
2020 - 10.1080/10428194.2019.1648806
Leukemia and Lymphoma, Vol. 61 Núm. 1 (february 2020) , p. 37-46
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
